MarketCap
Facebook
X
Telegram
Ampio Pharmaceuticals Financial Ratios 2023-2008 | AMPE
Brief overview of Ampio Pharmaceuticals's financial ratios
This overview follows the five latest available observations from 2016 through 2020.
The valuation comparison uses EV/EBITDA 240.94x (median 62.41x), P/S 236.02x (median 5,355.38x), P/B 0.2x (median 0.24x). On average, this basket is 133.6% above its own five-year medians. The market is pricing in elevated future expectations.
Capital efficiency is characterized by ROE -2.6%, ROA -150.5%, ROCE -75.2%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG of 0.61x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
Overall assessment
Ampio Pharmaceuticals's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios Ampio Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.0 | -0.4 | -18.6 | -5.7 | 1.4 | -2.8 | -2.4 | -3.5 | -7.4 | -11.4 | -11.4 | -5.5 | - | - | - |
P/S |
- | - | - | - | - | - | - | - | 236.0 | 13219.4 | 5453.1 | 2637.1 | 5355.4 | - | - | - |
EPS |
-10.7 | -21.7 | -1.3 | -0.1 | -0.1 | 0.5 | -0.8 | -0.1 | -0.6 | -0.8 | -0.6 | -0.3 | -0.7 | -0.5 | - | - |
EV (Enterprise Value) |
-1.05 M | -10.7 M | -15.7 M | 284 M | 79.4 M | 47.4 M | 186 M | 49 M | 96.3 M | 238 M | 249 M | 116 M | 90.8 M | 4.07 M | -72 K | - |
EBITDA per Share |
0.15 | 1.39 | 0.08 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | -0.62 | -0.77 | -0.62 | -0.346 | -0.426 | - | - | - |
EV/EBITDA |
-8.6 | -10.2 | -14.4 | 240.9 | 62.4 | 37.0 | 153.4 | 40.3 | -3.0 | -6.1 | -10.4 | 1862.2 | 2133.3 | - | - | - |
PEG |
-0.0 | -0.0 | -0.0 | 0.61 | 0.17 | -0.07 | 0.72 | 0.32 | -0.21 | 0.32 | 0.16 | -0.22 | 0.13 | - | - | - |
P/B |
0.2 | 0.0 | 0.2 | 16.9 | 12.2 | 8.8 | -4.2 | 7.1 | 2.9 | 4.3 | 8.2 | 5.5 | 5.7 | - | - | - |
P/CF |
-0.1 | -0.0 | -0.5 | -20.1 | -5.1 | -3.8 | -12.7 | -3.2 | -4.2 | -9.2 | -14.3 | -13.6 | -11.0 | - | - | - |
ROE % |
-256.90 | -138.58 | -62.58 | -90.74 | -211.55 | 649.08 | 151.83 | -288.86 | -86.52 | -57.66 | -72.58 | -48.65 | -103.38 | 200.91 | 564.58 | - |
ROA % |
-150.49 | -120.23 | -43.98 | -69.47 | -97.35 | 242.24 | -338.84 | -140.95 | -63.49 | -54.26 | -66.66 | -44.85 | -94.23 | -1091.95 | - | - |
ROCE % |
- | - | - | -75.24 | -191.17 | -88.44 | -136.10 | -149.04 | -75.73 | -58.10 | -71.91 | -48.82 | -61.21 | - | - | - |
Current Ratio |
2.4 | 7.6 | 3.4 | 4.3 | 1.9 | 1.6 | 0.3 | 2.0 | 4.0 | 14.6 | 12.8 | 12.8 | 11.3 | 0.2 | - | - |
DPO |
- | - | - | - | - | - | - | - | 4620.2 | 537.3 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | -4620.2 | -537.3 | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Ampio Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.53 | -0.09 | -0.26 | - | -0.43 | -0.01 | -0.02 | - | -0.02 | -0.02 | -0.02 | - | -0.02 | -0.02 | -0.03 | - | -0.05 | - | -0.05 | - | 0.06 | 0.05 | 0.27 | -0.58 | -0.06 | -0.04 | -0.03 | -0.06 | -0.07 | -0.1 | -0.13 | -0.14 | -0.14 | -0.14 | -0.14 | -0.19 | -0.18 | -0.17 | -0.23 | -0.17 | -0.16 | -0.17 | -0.11 | -0.1 | -0.07 | -0.08 | -0.09 | - | -0.09 | -0.1 | -0.49 |
EBITDA per Share |
0.15 | 0.01 | 0.01 | - | 0.06 | 0.02 | 0.02 | - | 0.06 | - | - | - | - | - | - | - | 0.01 | 0.01 | - | - | 0.01 | 0.01 | - | - | 0.01 | 0.01 | 0.01 | - | 0.02 | 0.01 | 0.01 | - | -0.13 | 0.01 | - | - | -0.18 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-140.55 | -127.99 | -132.41 | -81.92 | -102.92 | -74.09 | -85.65 | -60.32 | -91.73 | -113.78 | -356.18 | -334.32 | -508.81 | -473.62 | 811.28 | 1071.14 | 1330.49 | 1382.38 | 1626.23 | 384.38 | 510.57 | -1885.92 | -1833.82 | -2119.54 | -2296.29 | -200.00 | -167.93 | -167.60 | -144.08 | -119.63 | -95.51 | -69.85 | -57.79 | -54.35 | -51.15 | -51.06 | -58.26 | -61.60 | -86.62 | -92.93 | -86.17 | -79.55 | -61.67 | -62.03 | -66.30 | -76.40 | -107.56 | -88.90 | -19.71 | -19.76 | -49.43 |
ROA % |
-102.15 | -93.68 | -95.88 | -58.83 | -74.97 | -54.25 | -63.53 | -46.34 | -68.00 | -74.88 | -120.11 | -103.23 | -148.46 | -124.78 | -147.90 | -89.36 | -52.11 | 32.70 | 180.99 | 227.14 | -54.46 | -137.02 | -196.57 | -364.44 | -107.51 | -85.93 | -96.84 | -110.23 | -105.40 | -94.58 | -76.40 | -57.08 | -51.34 | -50.74 | -48.55 | -48.22 | -54.50 | -57.38 | -77.57 | -82.76 | -76.61 | -70.51 | -56.28 | -56.94 | -59.65 | -67.50 | -96.10 | -78.94 | -16.94 | -16.94 | -45.06 |
ROCE % |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.08 | - | - | - | -12.96 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
3.4 | 3.5 | 3.8 | 7.5 | 3.8 | 3.8 | 3.1 | 3.4 | 4.3 | 4.2 | 4.4 | 4.3 | 3.2 | 2.1 | 1.3 | 1.9 | 1.4 | 2.1 | 1.0 | 1.6 | 1.2 | 0.8 | 0.6 | 0.3 | 1.0 | 1.4 | 1.9 | 1.9 | 2.4 | 5.1 | 5.6 | 4.0 | 5.4 | 12.6 | 18.9 | 14.6 | 18.1 | 16.8 | 17.2 | 12.8 | 16.8 | 7.7 | 12.2 | 12.8 | 16.8 | 10.1 | 12.4 | 11.3 | 7.1 | 7.0 | 11.3 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1537.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 769.1 | 5839.9 | 2070.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1537.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -769.1 | -5030.0 | -1873.5 | - | 1537.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Ampio Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
